


substituted benzofuran-2-yl are substituted with R^3 , R^4 and R^5 and R^2 , R^3 , R^4 , R^5 , A^1 and A^2 are as defined herein



In another aspect, there is provided a compound as defined herein for use as therapeutically
5 active substance.

In another aspect, there is provided a pharmaceutical composition comprising a compound
as defined herein and a therapeutically inert carrier.

In another aspect, there is provided a compound as defined herein for use in the treatment
or prophylaxis of renal conditions, liver conditions, inflammatory conditions, conditions of the
10 nervous system, fibrotic diseases and acute and chronic organ transplant rejection.

In another aspect, there is provided the use of a compound as defined herein for the
preparation of a medicament for the treatment or prophylaxis of renal conditions, liver
conditions, inflammatory conditions, conditions of the nervous system, fibrotic diseases and
acute and chronic organ transplant rejection.

15 The term “alkenyl” denotes a monovalent linear or branched hydrocarbon group of 2 to 7
carbon atoms with at least one double bond. In particular embodiments, alkenyl has 2 to 4 carbon
atoms with at least one double bond. Examples of alkenyl include ethenyl, propenyl, prop-2-
enyl, isopropenyl, n-butenyl and iso-butenyl. Particular alkenyl group is ethenyl.

The term “alkoxy” denotes a group of the formula $-O-R'$, wherein R' is an alkyl group.
20 Examples of alkoxy group include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy
and tert-butoxy. Particular alkoxy group include isopropoxy.

pyridinyl, substituted pyridinyl, halogen, hydroxy, cyano, alkylsulfanyl, haloalkylsulfanyl, cycloalkylsulfanyl, alkylsulfinyl, haloalkylsulfinyl, cycloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, cycloalkylsulfonyl, alkylcarbonylamino, substituted aminosulfonyl, substituted amino and substituted aminoalkyl, wherein substituted aminosulfonyl, substituted amino and substituted aminoalkyl are substituted on the nitrogen atom with one to two substituents independently selected from H, alkyl, cycloalkyl, cycloalkylalkyl, hydroxyalkyl, alkoxyalkyl, alkylcarbonyl and cycloalkylcarbonyl, and wherein substituted phenyl and substituted pyridinyl are optionally substituted with one to three substituents independently selected from alkyl, halogen, haloalkyl, alkoxy and haloalkoxy;

R⁶ is H, alkyl, haloalkyl or cycloalkyl;

R⁷ and R⁸ are independently selected from H, alkyl, haloalkyl or cycloalkyl;

or pharmaceutically acceptable salts.

3. A compound according to claim 1 or 2, wherein R¹ is substituted phenylalkyl, substituted phenoxyalkyl or substituted phenylalkoxy, wherein substituted phenylalkyl, substituted phenoxyalkyl and substituted phenylalkoxy are substituted with R³, R⁴ and R⁵;
4. A compound according to any one of claims 1 to 3, wherein R¹ is substituted phenoxyalkyl or substituted phenylalkoxy, wherein substituted phenoxyalkyl and substituted phenylalkoxy are substituted with R³, R⁴ and R⁵;
5. A compound according to any one of claims 1 to 4, wherein R¹ is phenylalkoxy substituted with R³, R⁴ and R⁵;
6. A compound according to any one of claims 1 to 5, wherein R² is the ring system A.
7. A compound according to any one of claims 1 to 6, wherein A¹ is -N- and A² is -N- or -CR⁸-.

8. A compound according to any one of claims 1 to 7, wherein R^3 , R^4 and R^5 are independently selected from H, alkyl, cycloalkyl, heterocycloalkylalkoxy, haloalkoxy, halogen, cyano and alkylcarbonylamino.
9. A compound according to any one of claims 1 to 8, wherein R^3 , R^4 and R^5 are independently selected from H, alkyl, cycloalkyl, haloalkoxy, halogen, cyano and alkylcarbonylamino.
10. A compound according to any one of claims 1 to 9, wherein R^3 is heterocycloalkylalkoxy, haloalkoxy or cyano.
11. A compound according to any one of claims 1 to 10, wherein R^3 is haloalkoxy or cyano.
12. A compound according to any one of claims 1 to 11, wherein R^4 is H, alkyl, cycloalkyl or halogen.
13. A compound according to any one of claims 1 to 12, wherein R^4 is H, alkyl or halogen.
14. A compound according to any one of claims 1 to 13, wherein R^5 is H.
15. A compound according to any one of claims 1 to 14, wherein R^7 is H.
16. A compound according to any one of claims 1 to 15, wherein R^8 is H.
17. A compound according to any one of claims 1 to 16, wherein

R^1 is substituted phenylalkoxy substituted with R^3 , R^4 and R^5 ;

A^1 is -N-;

A^2 is -N- or -CR⁸-;

R^2 is the ring system A.

R^3 is haloalkoxy or cyano;

R^4 is H or halogen;

R^5 is H;

R^8 is H;

or pharmaceutically acceptable salts.

18. A compound according to any one of claims 1 to 17, selected from

Benzyl 2-(1,4,6,7-tetrahydrotriazolo[4,5-c]pyridine-5-carbonyl)-4,5,7,8-tetrahydropyrazolo[1,5-d][1,4]diazepine-6-carboxylate;

Benzyl 2-(1,4,6,7-tetrahydrotriazolo[4,5-c]pyridine-5-carbonyl)-5,6,8,9-tetrahydroimidazo[1,2-d][1,4]diazepine-7-carboxylate;

[3-Fluoro-4-(trifluoromethoxy)phenyl]methyl 2-(1,4,6,7-tetrahydrotriazolo[4,5-c]pyridine-5-carbonyl)-4,5,7,8-tetrahydropyrazolo[1,5-d][1,4]diazepine-6-carboxylate ;

2-Fluoro-4-(trifluoromethoxy)benzyl 2-(4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridine-5-carbonyl)-7,8-dihydro-4H-pyrazolo[1,5-d][1,4]diazepine-6(5H)-carboxylate ;

[4-(Trifluoromethoxy)phenyl]methyl 2-(1,4,6,7-tetrahydrotriazolo[4,5-c]pyridine-5-carbonyl)-4,5,7,8-tetrahydropyrazolo[1,5-d][1,4]diazepine-6-carboxylate ;

4-Cyanobenzyl 2-(4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridine-5-carbonyl)-7,8-dihydro-4H-pyrazolo[1,5-d][1,4]diazepine-6(5H)-carboxylate ;

4-Cyano-3-fluorobenzyl 2-(4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridine-5-carbonyl)-7,8-dihydro-4H-pyrazolo[1,5-d][1,4]diazepine-6(5H)-carboxylate ;

4-Cyano-2-fluorobenzyl 2-(4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridine-5-carbonyl)-7,8-dihydro-4H-pyrazolo[1,5-d][1,4]diazepine-6(5H)-carboxylate ;

(4-Cyano-2-propan-2-ylphenyl)methyl 2-(1,4,6,7-tetrahydrotriazolo[4,5-c]pyridine-5-carbonyl)-4,5,7,8-tetrahydropyrazolo[1,5-d][1,4]diazepine-6-carboxylate ;

[4-Cyano-2-(2,2-dimethylpropanoylamino)phenyl]methyl 2-(1,4,6,7-tetrahydrotriazolo[4,5-c]pyridine-5-carbonyl)-4,5,7,8-tetrahydropyrazolo[1,5-d][1,4]diazepine-6-carboxylate ;

[4-(Trifluoromethoxy)phenyl]methyl 2-(1,4,6,7-tetrahydrotriazolo[4,5-c]pyridine-5-carbonyl)-5,6,8,9-tetrahydro-[1,2,4]triazolo[1,5-d][1,4]diazepine-7-carboxylate ;

[3-fluoro-4-(trifluoromethoxy)phenyl]methyl 2-(1,4,6,7-tetrahydrotriazolo[4,5-c]pyridine-5-carbonyl)-5,6,8,9-tetrahydro-[1,2,4]triazolo[1,5-d][1,4]diazepine-7-carboxylate;

3-chloro-4-(trifluoromethoxy)benzyl 2-(4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridine-5-carbonyl)-7,8-dihydro-4H-pyrazolo[1,5-d][1,4]diazepine-6(5H)-carboxylate;

2-methoxy-4-(trifluoromethoxy)benzyl 2-(4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridine-5-carbonyl)-7,8-dihydro-4H-pyrazolo[1,5-d][1,4]diazepine-6(5H)-carboxylate;

2-methyl-4-(trifluoromethoxy)benzyl 2-(4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridine-5-carbonyl)-7,8-dihydro-4H-pyrazolo[1,5-d][1,4]diazepine-6(5H)-carboxylate;

4-(2,2,2-trifluoroethoxy)benzyl 2-(4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridine-5-carbonyl)-7,8-dihydro-4H-pyrazolo[1,5-d][1,4]diazepine-6(5H)-carboxylate;

[3-chloro-4-(trifluoromethoxy)phenyl]methyl 2-(1,4,6,7-tetrahydrotriazolo[4,5-c]pyridine-5-carbonyl)-5,6,8,9-tetrahydro-[1,2,4]triazolo[1,5-d][1,4]diazepine-7-carboxylate;

[3-chloro-4-(trifluoromethoxy)phenyl]methyl 2-(1,4,6,7-tetrahydrotriazolo[4,5-c]pyridine-5-carbonyl)-5,6,8,9-tetrahydroimidazo[1,2-d][1,4]diazepine-7-carboxylate;

3-fluoro-4-(trifluoromethoxy)benzyl 2-((3aR,7aR)-2-oxooctahydrooxazolo[5,4-c]pyridine-5-carbonyl)-8,9-dihydro-5H-[1,2,4]triazolo[1,5-d][1,4]diazepine-7(6H)-carboxylate;

and pharmaceutically acceptable salts thereof.

19. A compound according to any one of claims 1 to 18, selected from

Benzyl 2-(1,4,6,7-tetrahydrotriazolo[4,5-c]pyridine-5-carbonyl)-4,5,7,8-tetrahydropyrazolo[1,5-d][1,4]diazepine-6-carboxylate;

Benzyl 2-(1,4,6,7-tetrahydrotriazolo[4,5-c]pyridine-5-carbonyl)-5,6,8,9-tetrahydroimidazo[1,2-d][1,4]diazepine-7-carboxylate;

[3-Fluoro-4-(trifluoromethoxy)phenyl]methyl 2-(1,4,6,7-tetrahydrotriazolo[4,5-c]pyridine-5-carbonyl)-4,5,7,8-tetrahydropyrazolo[1,5-d][1,4]diazepine-6-carboxylate ;

2-Fluoro-4-(trifluoromethoxy)benzyl 2-(4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridine-5-carbonyl)-7,8-dihydro-4H-pyrazolo[1,5-d][1,4]diazepine-6(5H)-carboxylate ;

3-tert-Butyl-4-[2-oxo-2-[2-(1,4,6,7-tetrahydrotriazolo[4,5-c]pyridine-5-carbonyl)-4,5,7,8-tetrahydropyrazolo[1,5-d][1,4]diazepin-6-yl]ethoxy]benzonitrile;

and pharmaceutically acceptable salts thereof.

20. A compound according to any one of claims 1 to 18, selected from

(6-(2-cyclopropyl-6-((tetrahydro-2H-pyran-4-yl)methoxy)isonicotinoyl)-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-d][1,4]diazepin-2-yl)(6,7-dihydro-1H-[1,2,3]triazolo[4,5-c]pyridin-5(4H)-yl)methanone;

(E)-3-[4-(difluoromethoxy)-3-fluorophenyl]-1-[2-(1,4,6,7-tetrahydrotriazolo[4,5-c]pyridine-5-carbonyl)-4,5,7,8-tetrahydropyrazolo[1,5-d][1,4]diazepin-6-yl]prop-2-en-1-one;

4-(difluoromethoxy)-3-fluorobenzyl 2-(4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridine-5-carbonyl)-7,8-dihydro-4H-pyrazolo[1,5-d][1,4]diazepine-6(5H)-carboxylate;

[3-fluoro-4-(trifluoromethoxy)phenyl]methyl 2-(1,4,6,7-tetrahydrotriazolo[4,5-c]pyridine-5-carbonyl)-5,6,8,9-tetrahydro-[1,2,4]triazolo[1,5-d][1,4]diazepine-7-carboxylate;

3-chloro-4-(trifluoromethoxy)benzyl 2-(4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridine-5-carbonyl)-7,8-dihydro-4H-pyrazolo[1,5-d][1,4]diazepine-6(5H)-carboxylate;

2-methyl-4-(trifluoromethoxy)benzyl 2-(4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridine-5-carbonyl)-7,8-dihydro-4H-pyrazolo[1,5-d][1,4]diazepine-6(5H)-carboxylate;

[3-chloro-4-(trifluoromethoxy)phenyl]methyl 2-(1,4,6,7-tetrahydrotriazolo[4,5-c]pyridine-5-carbonyl)-5,6,8,9-tetrahydro-[1,2,4]triazolo[1,5-d][1,4]diazepine-7-carboxylate;

[3-chloro-4-(trifluoromethoxy)phenyl]methyl 2-(1,4,6,7-tetrahydrotriazolo[4,5-c]pyridine-5-carbonyl)-5,6,8,9-tetrahydroimidazo[1,2-d][1,4]diazepine-7-carboxylate;

and pharmaceutically acceptable salts thereof.

21. A compound according to any one of claims 1 to 19, selected from

3-Fluoro-4-(Trifluoromethoxy)benzyl 2-(4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridine-5-carbonyl)-7,8-dihydro-4H-pyrazolo[1,5-d][1,4]diazepine-6(5H)-carboxylate;

[4-(Trifluoromethoxy)phenyl]methyl 2-(1,4,6,7-tetrahydrotriazolo[4,5-c]pyridine-5-carbonyl)-4,5,7,8-tetrahydropyrazolo[1,5-d][1,4]diazepine-6-carboxylate;


[4-(Trifluoromethoxy)phenyl]methyl 2-(1,4,6,7-tetrahydrotriazolo[4,5-c]pyridine-5-carbonyl)-5,6,8,9-tetrahydro-[1,2,4]triazolo[1,5-d][1,4]diazepine-7-carboxylate;

[4-(Trifluoromethoxy)phenyl]methyl 2-(1,4,6,7-tetrahydrotriazolo[4,5-c]pyridine-5-carbonyl)-5,6,8,9-tetrahydroimidazo[1,2-d][1,4]diazepine-7-carboxylate;

3-tert-Butyl-4-[2-oxo-2-[2-(1,4,6,7-tetrahydrotriazolo[4,5-c]pyridine-5-carbonyl)-4,5,7,8-tetrahydropyrazolo[1,5-d][1,4]diazepin-6-yl]ethoxy]benzonitrile;


and pharmaceutically acceptable salts thereof.

22. A process to prepare a compound according to any one of claims 1 to 21 comprising the reaction of a compound of formula (II) in the presence of a compound of formula (III), wherein R^1 is phenylalkoxy substituted with R^3 , R^4 and R^5 , R_A is phenylalkyl substituted with R^3 , R^4 and R^5 and R^2 , R^3 , R^4 , R^5 , A^1 and A^2 are as defined in any one of claim 1 to 17



23. A process to prepare a compound according to any one of claims 1 to 21 comprising the reaction of a compound of formula (II) in the presence of a compound of formula (IV), wherein R^1 is alkyl, haloalkyl, substituted cycloalkyl, substituted cycloalkylalkyl, substituted phenyl, substituted phenylalkyl, substituted phenoxyalkyl, substituted phenylcycloalkyl, substituted phenylalkenyl, substituted phenylalkynyl, substituted pyridinyl, substituted pyridinylalkyl, substituted pyridinylalkenyl, substituted pyridinylalkynyl, substituted thiophenyl, substituted thiophenylalkyl, substituted thiophenylalkenyl, substituted thiophenylalkynyl, substituted 2,3-dihydro-1H-isoindol-2-yl, substituted 1H-indol-2-yl or substituted benzofuran-2-yl, wherein substituted cycloalkyl, substituted cycloalkylalkyl, substituted phenyl, substituted phenylalkyl, substituted phenoxyalkyl, substituted phenylcycloalkyl, substituted phenylalkenyl, substituted

phenylalkynyl, substituted pyridinyl, substituted pyridinylalkyl, substituted pyridinylalkenyl, substituted pyridinylalkynyl, substituted thiophenyl, substituted thiophenylalkyl, substituted thiophenylalkenyl, substituted thiophenylalkynyl, substituted 2,3-dihydro-1H-isoindol-2-yl, substituted 1H-indol-2-yl and substituted benzofuran-2-yl are substituted with R^3 , R^4 and R^5 and R^2 , R^3 , R^4 , R^5 A^1 and A^2 are as defined in any one of claim 1 to 17



24. A compound according to any one of claims 1 to 21 for use as therapeutically active substance.
25. A pharmaceutical composition comprising a compound according to any one of claims 1 to 21 and a therapeutically inert carrier.
26. A compound according to any one of claims 1 to 21 for use in the treatment or prophylaxis of renal conditions, liver conditions, inflammatory conditions, conditions of the nervous system, fibrotic diseases and acute and chronic organ transplant rejection.
27. The use of a compound according to any one of claims 1 to 21 for the preparation of a medicament for the treatment or prophylaxis of renal conditions, liver conditions, inflammatory conditions, conditions of the nervous system, fibrotic diseases and acute and chronic organ transplant rejection.